Rx for Legal Troubles: CEO Medical Degree and Corporate Litigation
研究发现，拥有医学学位的CEO所在制药公司更容易遭遇证券集体诉讼，但专利诉讼较少；市场对这类CEO的失败容忍度低，股价负面反应显著。
ABSTRACT Research Question/Issue This study examines the relationship between CEOs' medical degrees (MDs) and corporate litigations targeting US pharmaceutical firms. Research Findings/Insights CEOs with a medical background are significantly more susceptible to securities class actions, while facing fewer patent lawsuits. The results indicate that the lack of management skills among MD CEOs comes at the cost of firm value. After lawsuit announcements, companies led by MD CEOs experience a significantly negative effect on their stock prices. Markets show no tolerance for failures by MD CEOs, as evidenced by the impact of clinical trial disappointments. Theoretical/Academic Implications The findings contribute to our understanding of the impact of CEOs' medical backgrounds on corporate litigation outcomes. The results suggest that when examining how a CEO's qualifications affect legal issues and the value of a company, we should consider the unique context of having an MD. Practitioner/Policy Implications Practically, the study implies that firms should carefully consider the balance of managerial and medical expertise in CEO appointments, recognizing the potential legal and financial consequences. Policymakers might see it as beneficial to encourage a mix of different skills among top executives. This could make pharmaceutical companies more resilient in the face of legal issues, which, in turn, helps maintain confidence among investors.